Nasopharyngeal carcinoma is an Epstein‐Barr virus (EBV)‐associated tumor, and most NPC patients have evidence of infection by this virus.47 We used type I IFN to treat NPC cells and PBMCs to support it because IFNs have been best known for initiating an antiviral program of gene expression,48 although we did not directly discover the antiviral effects of TRIM26 in this study. This evidence concerns the gene TRIM26 and nasopharyngeal carcinoma.